Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

TheraSphere With Durvalumab and Tremelimumab for HCC

NCT: NCT05063565 · ACTIVE_NOT_RECRUITING

NCT IDNCT05063565
StatusACTIVE_NOT_RECRUITING
Start Date2023-11-03
Completion2027-06

Brief Summary

The objective of the ROWAN clinical study is to assess the efficacy of local tumor control in HCC patients who receive TheraSphere followed by durvalumab and tremelimumab.

Frequently Asked Questions

What is TheraSphere With Durvalumab and Tremelimumab for HCC?

TheraSphere With Durvalumab and Tremelimumab for HCC is a clinical trial registered under NCT05063565. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT05063565?

The current status of NCT05063565 (TheraSphere With Durvalumab and Tremelimumab for HCC) is: ACTIVE_NOT_RECRUITING.

When did TheraSphere With Durvalumab and Tremelimumab for HCC start?

TheraSphere With Durvalumab and Tremelimumab for HCC started on 2023-11-03.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑